history of sustained VT = LGE diagnosis: Not reported 18%; CRT-D implantation = 2%; NYHA class III–IV = 68%; medications: ACE inhibitor/ARB = 91%, = 95% Mean follow up: 3.2 years Looi et al. () Prospective N=103 patients with DCM who Inclusion criteria: Patients Scanner: 1.5-T scanner with a ICD implantation: Not described had a clinical presentation of with DCM, prospectively cohort synergy cardiac coil Outcomes: HF and an ECG identified between 1 Cardiac function sequence: demonstrating LVEF <50%: December 2003 and 31 New HR for likelihood of having: Electrocardiographically gated August 2006, were included Zealand NHMRC level II n=31 (30%) LGE+ steady-state free-precession cine all-cause mortality in the analysis if they had a n=72 (70%) LGE– images were acquired in the 2 and cardiac death clinical presentation of HF 4 chamber, LV outflow tract and HF and an ECG demonstrating Patient characteristics: SIGN: short-axis views. VA impaired LV systolic function unacceptable age = 58 ± 13 years; cardiac transplantation (LVEF <50%), and had LGE sequence: 3D quality with a high MACE successfully completed an segmented gradient-echo risk of bias male = 76%; LGE-CMR. sequence in LGE+ patients compared with those LVEF (CMR) = 32 ± 12%; that are LGE– Exclusion criteria: patients Contrast agent: 0.15 mmol/kg NYHA class: I = 75%, II = with ICA-documented Gd-based contrast agent 18%, III = 4% significant CAD (>50% DS in (Omniscan) Mean follow-up: 660 ± any coronary artery), 346 days Time delay: 10 minutes significant valvular disease, CM of known cause including LV function: LV end-diastolic and HCM, alcohol- or end-systolic volumes, and LVEF chemotherapy-induced or were calculated from the infiltrative CM cine images. LGE diagnosis: Areas of LGE
history of sustained VT = 18%; CRT-D implantation = 2%; NYHA class III–IV = 68%; medications: ACE inhibitor/ARB = 91%, = 95% Mean follow up: 3.2 years LGE diagnosis: Not reported Looi et al. () New Zealand Prospective cohort NHMRC level II SIGN: unacceptable quality with a high risk of bias N=103 patients with DCM who had a clinical presentation of HF and an ECG demonstrating LVEF <50%: n=31 (30%) LGE+ n=72 (70%) LGE– Patient characteristics: age = 58 ± 13 years; male = 76%; LVEF (CMR) = 32 ± 12%; NYHA class: I = 75%, II = 18%, III = 4% Mean follow-up: 660 ± 346 days Inclusion criteria: Patients with DCM, prospectively identified between 1 December 2003 and 31 August 2006, were included in the analysis if they had a clinical presentation of HF and an ECG demonstrating impaired LV systolic function (LVEF <50%), and had successfully completed an LGE-CMR. Exclusion criteria: patients with ICA-documented significant CAD (>50% DS in any coronary artery), significant valvular disease, CM of known cause including HCM, alcohol- or chemotherapy-induced or infiltrative CM Scanner: 1.5-T scanner with a synergy cardiac coil Cardiac function sequence: Electrocardiographically gated steady-state free-precession cine images were acquired in the 2 and 4 chamber, LV outflow tract and short-axis views. LGE sequence: 3D segmented gradient-echo sequence Contrast agent: 0.15 mmol/kg Gd-based contrast agent (Omniscan) Time delay: 10 minutes LV function: LV end-diastolic and end-systolic volumes, and LVEF were calculated from the cine images. LGE diagnosis: Areas of LGE ICD implantation: Not described Outcomes: HR for likelihood of having: all-cause mortality cardiac death HF VA cardiac transplantation MACE in LGE+ patients compared with those that are LGE–
1393-CMRforDCM.docx